Myriad Genetics (MYGN) Rating Lowered to C at TheStreet
A number of other brokerages also recently issued reports on MYGN. Barclays downgraded Myriad Genetics from an equal weight rating to an underweight rating and lowered their price target for the stock from $38.00 to $30.00 in a research report on Wednesday, September 5th. BidaskClub upgraded Myriad Genetics from a buy rating to a strong-buy rating in a research report on Wednesday, August 29th. Zacks Investment Research downgraded Myriad Genetics from a buy rating to a sell rating in a research report on Monday, August 27th. Bank of America raised their price target on Myriad Genetics from $31.00 to $34.00 and gave the stock a sell rating in a research report on Wednesday, August 22nd. Finally, ValuEngine lowered Myriad Genetics from a strong-buy rating to a buy rating in a research note on Wednesday, September 12th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $41.90.
Shares of MYGN opened at $30.85 on Thursday. The firm has a market capitalization of $2.33 billion, a P/E ratio of 25.71, a P/E/G ratio of 1.89 and a beta of 0.51. Myriad Genetics has a 52-week low of $27.27 and a 52-week high of $50.44. The company has a quick ratio of 2.86, a current ratio of 3.17 and a debt-to-equity ratio of 0.23.
A number of hedge funds have recently added to or reduced their stakes in MYGN. Royal Bank of Canada increased its stake in Myriad Genetics by 59.5% in the first quarter. Royal Bank of Canada now owns 4,597 shares of the company’s stock worth $136,000 after purchasing an additional 1,715 shares during the period. Robecosam AG increased its stake in Myriad Genetics by 39.8% in the second quarter. Robecosam AG now owns 4,193 shares of the company’s stock worth $156,000 after purchasing an additional 1,193 shares during the period. First Quadrant L P CA purchased a new stake in Myriad Genetics in the third quarter worth $201,000. Parametrica Management Ltd purchased a new stake in Myriad Genetics in the third quarter worth $204,000. Finally, Commonwealth Equity Services LLC purchased a new position in shares of Myriad Genetics during the second quarter valued at $205,000. Institutional investors and hedge funds own 96.75% of the company’s stock.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.